Retatrutide API and Research Peptide Supplier

What is Retatrutide?

Retatrutide is a single-chain synthetic peptide that acts as a triple receptor agonist, simultaneously activating the GLP-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon receptor (GCGR). The 39-amino-acid backbone is acylated with a C20 fatty di-acid moiety attached via a linker at the lysine residue at position 17, which drives albumin binding and an extended half-life.

Retatrutide (CAS 2381089-83-2, molecular formula C221H342N46O68, ~4731.33 g/mol) is described in the literature as a lyophilised powder. It is an investigational compound currently in Phase 3 clinical development for obesity and type 2 diabetes; it has not been approved by the FDA, EMA or any other regulator for any indication.

How Retatrutide Is Produced & Characterised

Retatrutide is a synthetically demanding multi-agonist peptide: the 39-mer length, the C20 fatty di-acid conjugation at Lys17 and the multiple non-native modifications all create opportunities for deletion sequences, diastereomers and incomplete acylation. Peptides of this class are typically produced by Fmoc solid-phase peptide synthesis (SPPS) with controlled side-chain conjugation, followed by preparative reverse-phase HPLC purification (often using dynamic axial compression columns) to resolve the target sequence from closely related impurities, and final lyophilisation to a stable powder.

Characterisation generally combines UPLC/HPLC for purity with LC-MS for sequence confirmation and impurity profiling. Additional release attributes commonly assessed for acylated peptides include water content, counter-ion (acetate or trifluoroacetate) content, residual solvents and peptide content.

Regulatory & Development Status

Retatrutide is an investigational active pharmaceutical ingredient. As of its most recent published status it is in Phase 3 clinical development for obesity and type 2 diabetes and has not been approved by the FDA, EMA or any other regulator for any indication. It is not an approved medicine and is not available as a finished pharmaceutical product.

For investigational peptides at this stage, sponsors compiling regulatory submissions generally reference CMC information through mechanisms such as Drug Master Files (e.g. US-DMF Type II) and CTD Module 3, alongside ICH-aligned analytical validation and stability data.

Research supply from Winhycare Pharma

Winhycare Pharma supplies research-grade Retatrutide to research organisations and individual researchers for research and development purposes. Material is supplied at high purity (>99%) under stringent quality control with QC documentation, in secure packaging through global standard logistics, with dedicated technical assistance from our team. We focus on consistent quality and purity, reliable and timely supply, confidential and professional service, and long-term partnerships.

Research use only. Not for human or veterinary use, and not for use in food, drugs, medical devices or cosmetics.

To enquire, tell us the quantity you need, the purity grade, the documentation you require and the destination country. The buyer is responsible for complying with the import and use regulations that apply to Retatrutide in their country.